Chaim Putterman

Prof. Chaim Putterman


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2019 in Nature Immunology
Verified
Journal Article
Open access
PDF file
TNthe Accelerating Medicines Partnership in SLE network
the Accelerating Medicines Partnership in SLE network
AAArnon Arazi
Arnon Arazi
DRDeepak A. Rao
Deepak A. Rao
CBCeline C. Berthier
Celine C. Berthier
ADAnne Davidson
Anne Davidson
BDBetty Diamond
Betty Diamond
Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is ineffective and often toxic. To develop mechanistic hypotheses of disease, we analyzed kidney samples from patients with lupus nephritis and from healthy control subjects using single-cell RNA sequencing. Our analysis revealed 21 subsets of leukocytes active in disease, including multiple populations of myeloid cells, T cells, natural killer cells and B cells that demonstrated both pro-inflammatory responses and inflammation-resolving responses. We found evidence of local activation of B cells correlated with an age-associated B-cell signature and evidence of progressive stages of monocyte differentiation within the kidney. A clear interferon response was observed in most cells. Two chemokine receptors, CXCR4 and CX3CR1, were broadly expressed, implying a potentially central role in cell trafficking. Gene expression of immune cells in urine and kidney was highly correlated, which would suggest that urine might serve as a surrogate for kidney biopsies.

18 January 2019 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
NSNoa Schwartz
Noa Schwartz
ASAriel D. Stock
Ariel D. Stock
CPChaim Putterman
Chaim Putterman

20 May 2019 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
TCthe Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium
the Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium
EDEvan Der
Evan Der
HSHemant Suryawanshi
Hemant Suryawanshi
PMPavel Morozov
Pavel Morozov
MKManjunath Kustagi
Manjunath Kustagi
CPChaim Putterman
Chaim Putterman

17 October 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
ABAlexandra V. Bocharnikov
Alexandra V. Bocharnikov
JKJoshua Keegan
Joshua Keegan
VWVanessa S. Wacleche
Vanessa S. Wacleche
YCYe Cao
Ye Cao
CFChamith Y. Fonseka
Chamith Y. Fonseka
DRDeepak A. Rao
Deepak A. Rao
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by pathologic T cell–B cell interactions and autoantibody production. Defining the T cell populations that drive B cell responses in SLE may enable design of therapies that specifically target pathologic cell subsets. Here, we evaluated the phenotypes of CD4 + T cells in the circulation of 52 SLE patients drawn from multiple cohorts and identified a highly expanded PD-1 hi CXCR5 – CD4 + T cell population. Cytometric, transcriptomic, and functional assays demonstrated that PD-1 hi CXCR5 – CD4 + T cells from SLE patients are T peripheral helper (Tph) cells, a CXCR5 – T cell population that stimulates B cell responses via IL-21. The frequency of Tph cells, but not T follicular helper (Tfh) cells, correlated with both clinical disease activity and the frequency of CD11c + B cells in SLE patients. PD-1 hi CD4 + T cells were found within lupus nephritis kidneys and correlated with B cell numbers in the kidney. Both IL-21 neutralization and CRISPR-mediated deletion of MAF abrogated the ability of Tph cells to induce memory B cell differentiation into plasmablasts in vitro. These findings identify Tph cells as a highly expanded T cell population in SLE and suggest a key role for Tph cells in stimulating pathologic B cell responses.

4 May 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
EDEvan Der
Evan Der
SRSaritha Ranabothu
Saritha Ranabothu
HSHemant Suryawanshi
Hemant Suryawanshi
KAKemal M. Akat
Kemal M. Akat
RCRobert Clancy
Robert Clancy
CPChaim Putterman
Chaim Putterman
Lupus nephritis is a leading cause of mortality among systemic lupus erythematosus (SLE) patients, and its heterogeneous nature poses a significant challenge to the development of effective diagnostics and treatments. Single cell RNA sequencing (scRNA-seq) offers a potential solution to dissect the heterogeneity of the disease and enables the study of similar cell types distant from the site of renal injury to identify novel biomarkers. We applied scRNA-seq to human renal and skin biopsy tissues and demonstrated that scRNA-seq can be performed on samples obtained during routine care. Chronicity index, IgG deposition, and quantity of proteinuria correlated with a transcriptomic-based score composed of IFN-inducible genes in renal tubular cells. Furthermore, analysis of cumulative expression profiles of single cell keratinocytes dissociated from nonlesional, non–sun-exposed skin of patients with lupus nephritis also revealed upregulation of IFN-inducible genes compared with keratinocytes isolated from healthy controls. This indicates the possible use of scRNA-seq analysis of skin biopsies as a biomarker of renal disease. These data support the potential utility of scRNA-seq to provide new insights into the pathogenesis of lupus nephritis and pave the way for exploiting a readily accessible tissue to reflect injury in the kidney.

24 May 2023 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
CMChandra Mohan
Chandra Mohan
TZTing Zhang
Ting Zhang
CPChaim Putterman
Chaim Putterman